NUVALENT, INC.

Nuvalent, Inc. (NUVL) is a clinical‑stage biotechnology company focused on precision oncology, developing targeted small‑molecule therapies against specific genetic drivers of cancer. With a market capitalisation of about $7.01 billion, the company’s value is largely driven by clinical trial progress, safety and efficacy readouts, regulatory milestones and potential collaborations or licensing deals rather than product revenue. Investors should expect higher volatility common to clinical‑stage biotechs: favourable trial results or partnerships can lift sentiment, while setbacks, delays or disappointing data can lead to sharp declines. Like many peers, Nuvalent may require additional funding as programmes advance, which can dilute existing shareholders. This summary is educational only and not personalised investment advice; prospective investors should assess their risk tolerance, consult multiple information sources (regulatory filings, clinical data and company statements) and consider professional financial guidance.